REGENXBIO’s Senior Director and Clinical Development Lead, Dr. Jahannaz Dastgir and Dr. Veerapandiyan from Arkansas Children’s Hospital share updates about RGX-202, an investigational gene therapy for the treatment of Duchenne […]
A Clinical Trial Investigating the Potential for AOC 1044 to Treat Individuals with DMD Mutations Amenable to Exon 44 Skipping Join Cure Duchenne’s webinar as we welcome Kelly DiTrapani and […]
Historically, a lower extremity fracture for an ambulatory individual with Duchenne likely meant that they would never walk again. Thankfully, for many individuals in recent years, this was not their […]
This webinar highlights a summary of an article about the Cincinnati study, which was published in the Journal of Comparative Effectiveness Research in January 2020. The study researchers wanted to […]
Join Edgewise Chief Scientific Officer and Chief Medical Officer to learn more about the clinical development program for EDG-5506, a myosin modulator, in Becker and Duchenne muscular dystrophies. The presentation […]
Moving from Bench to Clinic to Deliver a Potentially Transformative Therapy for Duchenne Muscular Dystrophy Join us for a Fireside Chat discussing Dyne’s Phase 1/2 clinical trial, DELIVER, evaluating DYNE-251 […]
Dr. Paolo Bettica will review recently completed study analysis for the Italfarmaco Phase 3 randomized controlled trial of givinostat in boys with Duchenne muscular dystrophy (DMD). He will answer your […]
The “What?”, “When?” and “How?” that everyone is asking. This webinar will leave you with a better understanding of the different types of treatments and cures for Duchenne that are […]
Pfizer’s Global Clinical Lead for Rare Neurological Diseases, Beth Belluscio, MD-PhD, and Debra Miller, Founder and CEO of CureDuchenne, sat down to educate the Duchenne community on Pfizer’s CIFFREO Trial […]